Details

Project TitleBiomarkers for Glioma Treatment Response
Track Code2014-031
Short Description

Method for predicting malignant glioma patient response to chemotherapy and radiotherapy based on STAT3 pathway signaling

#therapeutics #biomarkers #biomedical #healthcare #diagnostictool

Abstract

Northwestern University researchers have developed a method for discriminating between glioma patients who will and will not respond to chemo- and radiotherapy treatment. While many therapies for cancer exist, it has been well understood in the cancer research community that gene expression between two patients with identical cancer classifications impacts how the two patients respond to therapy. This understanding has led clinicians to try to tailor their therapeutic approaches to each patient, but this task is made more difficult by the fact that genetic factors affecting therapy response are not always known. The Horvath group at Northwestern University has identified a set of 5 genes from the STAT 3 pathway, whose expression can be used to predict how high-risk malignant glioma patients will respond to therapy. This innovative approach to glioma treatment is cost-effective and simple to implement in treatment and clinical trial settings. In addition to helping improve patient outcomes, this invention could make an impact on drug discovery and pharmacogenomic studies as well. 

 
Tagsbiomedical, HEALTHCARE: Diagnostic Tool, THERAPEUTICS: biomarker
 
Posted DateMar 3, 2015 5:25 PM

Inventor(s)

Robert Tell

Curt Horvath*

Applications

  • Pharmacogenomics
  • Clinical trials
  • Drug discovery studies
  • Targeted cancer therapies

Advantages

  • High accuracy and specificity
  • Inexpensive
  • Simple to implement

Publications

IP Status

Provisional patent application has been filed. 

Contact Information

Gwendolyn Humphreys, PhD

Invention Associate 

(p) 847-467-0308

(e) gwendolyn.humphreys@northwestern.edu